Do analysts prefer PRLD or JATT?

Prelude Therapeutics currently has a consensus price target of $7.67, suggesting a potential upside of 55.51%. Given Prelude Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Prelude Therapeutics is more favorable than JATT Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prelude Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings and valuation, PRLD or JATT?

JATT Acquisition has lower revenue, but higher earnings than Prelude Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Prelude Therapeutics $16.72M 23.48 -$99.50M -$1.00 N/A JATT Acquisition N/A N/A $6.85M N/A N/A

Is PRLD or JATT more profitable?

JATT Acquisition's return on equity of -49.58% beat Prelude Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Prelude Therapeutics N/A -118.24% -66.12% JATT Acquisition N/A -49.58% 2.84%

Does the media favor PRLD or JATT?

In the previous week, Prelude Therapeutics had 1 more articles in the media than JATT Acquisition. MarketBeat recorded 2 mentions for Prelude Therapeutics and 1 mentions for JATT Acquisition. Prelude Therapeutics' average media sentiment score of 0.94 beat JATT Acquisition's score of 0.00 indicating that Prelude Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Prelude Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive JATT Acquisition 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend JATT or GLSI?

Greenwich LifeSciences has a consensus price target of $47.50, indicating a potential upside of 104.30%. Given Greenwich LifeSciences' stronger consensus rating and higher possible upside, analysts clearly believe Greenwich LifeSciences is more favorable than JATT Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Greenwich LifeSciences 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has higher valuation and earnings, JATT or GLSI?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio JATT Acquisition N/A N/A $6.85M N/A N/A Greenwich LifeSciences N/A N/A -$19.36M -$1.57 N/A

Is JATT or GLSI more profitable?

JATT Acquisition's return on equity of -49.58% beat Greenwich LifeSciences' return on equity. Company Net Margins Return on Equity Return on Assets JATT Acquisition N/A -49.58% 2.84% Greenwich LifeSciences N/A -941.15% -368.53%

Which has higher valuation & earnings, ELYM or JATT?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Eliem Therapeutics N/A N/A -$35.12M -$0.53 N/A JATT Acquisition N/A N/A $6.85M N/A N/A

Is ELYM or JATT more profitable?

Eliem Therapeutics' return on equity of -47.03% beat JATT Acquisition's return on equity. Company Net Margins Return on Equity Return on Assets Eliem Therapeutics N/A -47.03% -45.97% JATT Acquisition N/A -49.58% 2.84%

Do analysts prefer UPB or JATT?

Upstream Bio currently has a consensus price target of $33.17, suggesting a potential upside of 378.60%. Given Upstream Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Upstream Bio is more favorable than JATT Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Upstream Bio 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43 JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, UPB or JATT?

JATT Acquisition has lower revenue, but higher earnings than Upstream Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Upstream Bio $2.85M 132.33 -$143.44M -$2.91 N/A JATT Acquisition N/A N/A $6.85M N/A N/A

Does the media prefer UPB or JATT?

In the previous week, Upstream Bio had 3 more articles in the media than JATT Acquisition. MarketBeat recorded 4 mentions for Upstream Bio and 1 mentions for JATT Acquisition. Upstream Bio's average media sentiment score of 1.09 beat JATT Acquisition's score of 0.00 indicating that Upstream Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Upstream Bio 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive JATT Acquisition 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts prefer AMRN or JATT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Amarin 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 2.50 JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings and valuation, AMRN or JATT?

JATT Acquisition has lower revenue, but higher earnings than Amarin. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Amarin $216.76M 1.54 -$38.80M -$0.65 N/A JATT Acquisition N/A N/A $6.85M N/A N/A

Does the media favor AMRN or JATT?

In the previous week, Amarin had 1 more articles in the media than JATT Acquisition. MarketBeat recorded 2 mentions for Amarin and 1 mentions for JATT Acquisition. Amarin's average media sentiment score of 0.93 beat JATT Acquisition's score of 0.00 indicating that Amarin is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amarin 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive JATT Acquisition 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

JATT Acquisition (JATT) Competitors

$11.75 +1.35 (+12.98%)

Closing price 06/29/2026 03:59 PM Eastern

Extended Trading

$11.07 -0.68 (-5.82%)

As of 06/29/2026 05:56 PM Eastern

Compare

JATT vs. PRLD, GLSI, ELYM, UPB, and AMRN

Should you buy JATT Acquisition stock or one of its competitors? MarketBeat compares JATT Acquisition with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with JATT Acquisition include Prelude Therapeutics (PRLD), Greenwich LifeSciences (GLSI), Eliem Therapeutics (ELYM), Upstream Bio (UPB), and Amarin (AMRN). These companies are all part of the "pharmaceutical products" industry.

How does JATT Acquisition compare to Prelude Therapeutics?

Prelude Therapeutics (NASDAQ:PRLD) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, earnings, institutional ownership, risk, media sentiment, valuation, profitability and analyst recommendations.

79.7% of Prelude Therapeutics shares are owned by institutional investors. Comparatively, 48.0% of JATT Acquisition shares are owned by institutional investors. 49.2% of Prelude Therapeutics shares are owned by company insiders. Comparatively, 20.0% of JATT Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

JATT Acquisition's return on equity of -49.58% beat Prelude Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Prelude Therapeutics	N/A	-118.24%	-66.12%
JATT Acquisition	N/A	-49.58%	2.84%

In the previous week, Prelude Therapeutics had 1 more articles in the media than JATT Acquisition. MarketBeat recorded 2 mentions for Prelude Therapeutics and 1 mentions for JATT Acquisition. Prelude Therapeutics' average media sentiment score of 0.94 beat JATT Acquisition's score of 0.00 indicating that Prelude Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Prelude Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
JATT Acquisition	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Prelude Therapeutics currently has a consensus price target of $7.67, suggesting a potential upside of 55.51%. Given Prelude Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Prelude Therapeutics is more favorable than JATT Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

JATT Acquisition has lower revenue, but higher earnings than Prelude Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Prelude Therapeutics	$16.72M	23.48	-$99.50M	-$1.00	N/A
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A

Summary

Prelude Therapeutics beats JATT Acquisition on 8 of the 11 factors compared between the two stocks.

How does JATT Acquisition compare to Greenwich LifeSciences?

JATT Acquisition (NYSE:JATT) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings, media sentiment and dividends.

JATT Acquisition's return on equity of -49.58% beat Greenwich LifeSciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
JATT Acquisition	N/A	-49.58%	2.84%
Greenwich LifeSciences	N/A	-941.15%	-368.53%

48.0% of JATT Acquisition shares are held by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are held by institutional investors. 20.0% of JATT Acquisition shares are held by company insiders. Comparatively, 51.5% of Greenwich LifeSciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Greenwich LifeSciences has a consensus price target of $47.50, indicating a potential upside of 104.30%. Given Greenwich LifeSciences' stronger consensus rating and higher possible upside, analysts clearly believe Greenwich LifeSciences is more favorable than JATT Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Greenwich LifeSciences	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, JATT Acquisition and JATT Acquisition both had 1 articles in the media. Greenwich LifeSciences' average media sentiment score of 1.89 beat JATT Acquisition's score of 0.00 indicating that Greenwich LifeSciences is being referred to more favorably in the news media.

Company	Overall Sentiment
JATT Acquisition	Neutral
Greenwich LifeSciences	Very Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A
Greenwich LifeSciences	N/A	N/A	-$19.36M	-$1.57	N/A

Summary

Greenwich LifeSciences beats JATT Acquisition on 5 of the 9 factors compared between the two stocks.

How does JATT Acquisition compare to Eliem Therapeutics?

Eliem Therapeutics (NASDAQ:ELYM) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation and profitability.

Eliem Therapeutics' return on equity of -47.03% beat JATT Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eliem Therapeutics	N/A	-47.03%	-45.97%
JATT Acquisition	N/A	-49.58%	2.84%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eliem Therapeutics	N/A	N/A	-$35.12M	-$0.53	N/A
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A

In the previous week, JATT Acquisition had 1 more articles in the media than Eliem Therapeutics. MarketBeat recorded 1 mentions for JATT Acquisition and 0 mentions for Eliem Therapeutics. Eliem Therapeutics' average media sentiment score of 0.00 equaled JATT Acquisition'saverage media sentiment score.

Company	Overall Sentiment
Eliem Therapeutics	Neutral
JATT Acquisition	Neutral

69.8% of Eliem Therapeutics shares are held by institutional investors. Comparatively, 48.0% of JATT Acquisition shares are held by institutional investors. 4.7% of Eliem Therapeutics shares are held by insiders. Comparatively, 20.0% of JATT Acquisition shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

JATT Acquisition beats Eliem Therapeutics on 4 of the 6 factors compared between the two stocks.

How does JATT Acquisition compare to Upstream Bio?

Upstream Bio (NASDAQ:UPB) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, analyst recommendations, dividends, profitability, valuation, risk and earnings.

48.0% of JATT Acquisition shares are held by institutional investors. 16.5% of Upstream Bio shares are held by company insiders. Comparatively, 20.0% of JATT Acquisition shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Upstream Bio had 3 more articles in the media than JATT Acquisition. MarketBeat recorded 4 mentions for Upstream Bio and 1 mentions for JATT Acquisition. Upstream Bio's average media sentiment score of 1.09 beat JATT Acquisition's score of 0.00 indicating that Upstream Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Upstream Bio	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
JATT Acquisition	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

JATT Acquisition has lower revenue, but higher earnings than Upstream Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Upstream Bio	$2.85M	132.33	-$143.44M	-$2.91	N/A
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A

JATT Acquisition has a net margin of 0.00% compared to Upstream Bio's net margin of -4,718.96%. Upstream Bio's return on equity of -43.82% beat JATT Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Upstream Bio	-4,718.96%	-43.82%	-42.27%
JATT Acquisition	N/A	-49.58%	2.84%

Upstream Bio currently has a consensus price target of $33.17, suggesting a potential upside of 378.60%. Given Upstream Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Upstream Bio is more favorable than JATT Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Upstream Bio	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Upstream Bio beats JATT Acquisition on 7 of the 12 factors compared between the two stocks.

How does JATT Acquisition compare to Amarin?

Amarin (NASDAQ:AMRN) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, profitability, institutional ownership, dividends, media sentiment and valuation.

JATT Acquisition has lower revenue, but higher earnings than Amarin.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarin	$216.76M	1.54	-$38.80M	-$0.65	N/A
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A

JATT Acquisition has a net margin of 0.00% compared to Amarin's net margin of -15.51%. Amarin's return on equity of -2.99% beat JATT Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amarin	-15.51%	-2.99%	-2.07%
JATT Acquisition	N/A	-49.58%	2.84%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarin	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.50
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

22.3% of Amarin shares are owned by institutional investors. Comparatively, 48.0% of JATT Acquisition shares are owned by institutional investors. 4.2% of Amarin shares are owned by company insiders. Comparatively, 20.0% of JATT Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Amarin had 1 more articles in the media than JATT Acquisition. MarketBeat recorded 2 mentions for Amarin and 1 mentions for JATT Acquisition. Amarin's average media sentiment score of 0.93 beat JATT Acquisition's score of 0.00 indicating that Amarin is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amarin	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
JATT Acquisition	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Amarin beats JATT Acquisition on 6 of the 11 factors compared between the two stocks.

Get JATT Acquisition News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JATT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JATT vs. The Competition

Export

Metric	JATT Acquisition	Biological Products Industry	Medical Sector	NYSE Exchange
Market Cap	$94.29M	$351.78M	$6.85B	$23.30B
Dividend Yield	N/A	N/A	2.66%	4.07%
P/E Ratio	N/A	N/A	26.04	31.73
Price / Sales	N/A	194.38	550.14	21.11
Price / Cash	27.08	22.44	29.09	18.60
Price / Book	-22.17	4.87	10.98	4.78
Net Income	$6.85M	-$141.03M	$3.57B	$1.07B
7 Day Performance	12.98%	1.31%	2.60%	1.47%
1 Month Performance	11.80%	-1.59%	0.93%	0.77%
1 Year Performance	1,019.05%	82.12%	36.40%	25.25%

JATT Acquisition Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JATT JATT Acquisition	N/A	$11.75 +13.0%	N/A	+1,019.0%	$94.29M	N/A	N/A	3	News Coverage Gap Up High Trading Volume
PRLD Prelude Therapeutics	3.6526 of 5 stars	$4.32 flat	$7.67 +77.5%	+527.8%	$344.07M	$12.14M	N/A	120	Gap Down High Trading Volume
GLSI Greenwich LifeSciences	2.2358 of 5 stars	$23.38 flat	$47.50 +103.2%	+158.6%	$343.18M	N/A	N/A	3	Positive News
ELYM Eliem Therapeutics	N/A	$11.45 +1.0%	N/A	+1,008.5%	$340.66M	N/A	N/A	9	High Trading Volume
UPB Upstream Bio	2.3171 of 5 stars	$6.25 flat	$33.17 +430.7%	-36.6%	$340.12M	$2.85M	N/A	38

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:JATT) was last updated on 6/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

JATT Acquisition (JATT) Competitors

JATT vs. PRLD, GLSI, ELYM, UPB, and AMRN

How does JATT Acquisition compare to Prelude Therapeutics?

Summary

How does JATT Acquisition compare to Greenwich LifeSciences?

Summary

How does JATT Acquisition compare to Eliem Therapeutics?

Summary

How does JATT Acquisition compare to Upstream Bio?

Summary

How does JATT Acquisition compare to Amarin?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JATT vs. The Competition

JATT Acquisition Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

JATT Acquisition (JATT) Competitors

JATT vs. PRLD, GLSI, ELYM, UPB, and AMRN

How does JATT Acquisition compare to Prelude Therapeutics?

Do insiders and institutionals hold more shares of PRLD or JATT?

Is PRLD or JATT more profitable?

Does the media favor PRLD or JATT?

Do analysts prefer PRLD or JATT?

Which has preferable earnings and valuation, PRLD or JATT?

Summary

How does JATT Acquisition compare to Greenwich LifeSciences?

Is JATT or GLSI more profitable?

Do institutionals and insiders hold more shares of JATT or GLSI?

Do analysts recommend JATT or GLSI?

Does the media prefer JATT or GLSI?

Which has higher valuation and earnings, JATT or GLSI?

Summary

How does JATT Acquisition compare to Eliem Therapeutics?

Is ELYM or JATT more profitable?

Which has higher valuation & earnings, ELYM or JATT?

Does the media refer more to ELYM or JATT?

Do institutionals & insiders hold more shares of ELYM or JATT?

Summary

How does JATT Acquisition compare to Upstream Bio?

Do institutionals & insiders believe in UPB or JATT?

Does the media prefer UPB or JATT?

Which has preferable earnings & valuation, UPB or JATT?

Is UPB or JATT more profitable?

Do analysts prefer UPB or JATT?

Summary

How does JATT Acquisition compare to Amarin?

Which has preferable earnings and valuation, AMRN or JATT?

Is AMRN or JATT more profitable?

Do analysts prefer AMRN or JATT?

Do insiders and institutionals hold more shares of AMRN or JATT?

Does the media favor AMRN or JATT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JATT vs. The Competition

JATT Acquisition Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools